ANRO vs. ORMP

Last updated Apr 1, 2026

Compare and contrast key facts about Alto Neuroscience, Inc (ANRO) and Oramed Pharmaceuticals Inc. (ORMP).

Performance

ANRO vs. ORMP - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Alto Neuroscience, Inc (ANRO) and Oramed Pharmaceuticals Inc. (ORMP). The values are adjusted to include any dividend payments, if applicable.

ANRO vs. ORMP - Yearly Performance Comparison

	2026 (YTD)	2025	2024
ANRO Alto Neuroscience, Inc	26.29%	320.80%	-79.57%
ORMP Oramed Pharmaceuticals Inc.	27.97%	17.77%	-12.00%

Fundamentals

EPS ANRO : -$2.20 ORMP : $1.03
Total Revenue (TTM) ANRO : $0.00 ORMP : $2.00M
Gross Profit (TTM) ANRO : -$421.00K ORMP : -$79.00K
EBITDA (TTM) ANRO : -$61.63M ORMP : $58.42M

Returns By Period

In the year-to-date period, ANRO achieves a 26.29% return, which is significantly lower than ORMP's 27.97% return.

ANRO

• 1D: 12.51%
• 1M: 14.17%
• YTD: 26.29%
• 6M: 459.20%
• 1Y: 940.74%
• 3Y*: —
• 5Y*: —
• 10Y*: —

ORMP

• 1D: 3.66%
• 1M: -0.44%
• YTD: 27.97%
• 6M: 38.15%
• 1Y: 70.42%
• 3Y*: 18.71%
• 5Y*: -18.59%
• 10Y*: -6.63%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

ANRO vs. ORMP — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ANRO

ANRO Risk / Return Rank: 99
ANRO Sharpe Ratio Rank: 100
ANRO Sortino Ratio Rank: 99
ANRO Omega Ratio Rank: 98
ANRO Calmar Ratio Rank: 100
ANRO Martin Ratio Rank: 100

ORMP

ORMP Risk / Return Rank: 83
ORMP Sharpe Ratio Rank: 84
ORMP Sortino Ratio Rank: 83
ORMP Omega Ratio Rank: 77
ORMP Calmar Ratio Rank: 88
ORMP Martin Ratio Rank: 84

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ANRO vs. ORMP - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Alto Neuroscience, Inc (ANRO) and Oramed Pharmaceuticals Inc. (ORMP). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	ANRO	ORMP	Difference
Sharpe ratio Return per unit of total volatility	7.25	1.45	+5.80
Sortino ratio Return per unit of downside risk	5.65	2.28	+3.38
Omega ratio Gain probability vs. loss probability	1.71	1.26	+0.45
Calmar ratio Return relative to maximum drawdown	30.09	3.44	+26.64
Martin ratio Return relative to average drawdown	72.94	7.67	+65.27
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

ANRO vs. ORMP - Sharpe Ratio Comparison

The current ANRO Sharpe Ratio is 7.25, which is higher than the ORMP Sharpe Ratio of 1.45. The chart below compares the historical Sharpe Ratios of ANRO and ORMP, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	ANRO	ORMP	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	7.25	1.45	+5.80
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	—	-0.23	—
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	-0.09	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.03	-0.06	+0.10

Correlation

The correlation between ANRO and ORMP is 0.09, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

ANRO vs. ORMP - Dividend Comparison

ANRO has not paid dividends to shareholders, while ORMP's dividend yield for the trailing twelve months is around 7.35%.

	TTM
ANRO Alto Neuroscience, Inc	0.00%
ORMP Oramed Pharmaceuticals Inc.	7.35%

Drawdowns

ANRO vs. ORMP - Drawdown Comparison

The maximum ANRO drawdown since its inception was -91.74%, roughly equal to the maximum ORMP drawdown of -94.25%. Use the drawdown chart below to compare losses from any high point for ANRO and ORMP.

Drawdown Indicators

	ANRO	ORMP	Difference
Max Drawdown Largest peak-to-trough decline	-91.74%	-94.25%	+2.51%
Max Drawdown (1Y) Largest decline over 1 year	-29.59%	-18.89%	-10.70%
Max Drawdown (5Y) Largest decline over 5 years	—	-94.25%	—
Max Drawdown (10Y) Largest decline over 10 years	—	-94.25%	—
Current Drawdown Current decline from peak	-7.45%	-87.74%	+80.29%
Average Drawdown Average peak-to-trough decline	-56.91%	-70.62%	+13.71%
Ulcer Index Depth and duration of drawdowns from previous peaks	12.21%	8.48%	+3.73%

Volatility

ANRO vs. ORMP - Volatility Comparison

Alto Neuroscience, Inc (ANRO) has a higher volatility of 24.93% compared to Oramed Pharmaceuticals Inc. (ORMP) at 14.54%. This indicates that ANRO's price experiences larger fluctuations and is considered to be riskier than ORMP based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	ANRO	ORMP	Difference
Volatility (1M) Calculated over the trailing 1-month period	24.93%	14.54%	+10.39%
Volatility (6M) Calculated over the trailing 6-month period	98.02%	37.14%	+60.88%
Volatility (1Y) Calculated over the trailing 1-year period	131.26%	48.81%	+82.45%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	118.76%	81.19%	+37.57%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	118.76%	72.78%	+45.98%

Financials